N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical by unknown
RESEARCH PAPER
N-glycan PK Profiling Using a High Sensitivity nanoLCMS
Work-Flow with Heavy Stable Isotope Labeled Internal
Standard and Application to a Preclinical Study of an IgG1
Biopharmaceutical
Fabian Higel 1 & Andreas Seidl 1 & Uwe Demelbauer7 & Margot Viertlboeck-Schudy2 & Vera Koppenburg2 & Ulrich Kronthaler3 &
Fritz Sörgel4,5 & Wolfgang Frieß6
Received: 10 December 2014 /Accepted: 21 May 2015 /Published online: 28 May 2015
# The Author(s) 2015
ABSTRACT
Purpose In this study an innovative, highly sensitive work-
flow is presented that allows the analysis of a possible influence
of individual glyco-variants on pharmacokinetics already dur-
ing pre-clinical development. Possible effects on the pharma-
cokinetics caused by glyco-variants have been subject of sev-
eral studies with in part contradictory results which can be
related to differences in the set-up.
Methods Using 96-well plate based affinity purification an
IgG1 antibodywas isolated from preclinical samples and glycans
were analyzed individually by nanoLCMS. Prerequisite was a
reference standard based on stable heavy isotope labeled gly-
cans. The high sensitivity and low sample consumption enabled
the integration into the preclinical development program.
Results The data of an IgG1 biopharmaceutical from a preclin-
ical rabbit study showed that someN-glycoforms have a different
PK profile compared with the average of all molecule variants as
determined by ELISA. IgG1 high mannose glycoforms M5 and
M6 were removed from circulation at a higher rate.
Conclusion The results of the preclinical study demonstrated
the applicability of the developed innovative workflow. The
PK profile of glyco-variants could be determined individually.
It was concluded that M6 was converted by mannosidases in
circulation to M5 which in turn was selectively cleared by
mannose receptor binding which is in-line with previously
published results. Therefore the developed technology de-
livers reliable results and can be applied for PK profiling of
other mAbs and other types of biopharmaceuticals.
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ABBREVIATIONS
2-AA 2-Aminobenzoic acid
AUC Area under the curve
DMSO Dimethyl sulfoxide
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EIC Extracted ion chromatogram
ELISA Enzyme linked immunosorbent assay
Fab Fragment antigen binding
Fc Fragment crystalizable
IgG Immunoglobulin G
LC-MS Liquid chromatography- Mass spectrometry
LLOQ Lower limit of quantification
LOD Limit of detection
NHS N-hydroxysuccinimide
PBS Phosphate buffered saline
PK Pharmacokinetics
PNGaseF Peptide N-Glycosidase F
t1/2 Elimination half-life
tmax Time until the maximal concentration is
reached
ULOQ Upper limit of quantification
INTRODUCTION
N-glycosylation, one of the most complex post-translational
modifications is under suspicion to influence the pharmacoki-
netics of therapeutic proteins. One class of therapeutic proteins,
mAbs that carry one N-glycan per heavy chain at their Fc part
were subject of several studies.(1–3) For example Newkirk et al.
generated degalactosylated IgG1 and IgG2 and showed that
the degalactosylated mAb was cleared at a slower rate in
mice.(4) In another study an IgG enriched in high mannose
glyco-structures was compared to complex glycosylated IgG.
No difference in PK was found by ELISA. Fab glycosylation
was investigated too via enrichment of an IgG to contain one
N-glycosylation in its variable domain. However no influence
on PK was observed.(5) The major drawback of enrichment
experiments is the generation of an artificial new IgG N-
glycoform pattern that does not necessarily give the same results
as the individual glycoforms in the original IgG. LC-MS based
approaches allow the direct analysis of the N-glycosylation from
the heterogenic mAb N-glycoform mixture. Using an LC-MS
method an increasing clearance of highmannoseN-glycans was
reported by several groups.(6–10) With a single subject case
study Chen et al. were the first to describe a conversion of high
mannose glycansM6-M9 toM5 on an IgG2 which occurred in
the blood stream due to circulating glycosidases.(6) The same
group showed for an IgG1 an increased clearance of M5
glycoforms in addition to this conversion.(7) Alessandri et al. re-
ported a conversion of M6 and M7 to M5 in circulation in vitro
and increased in vivo clearance of the high mannose glycans
compared to complex structures.(9) Using mAbs exclusively
glycosylated withM8/9 orM5, studies were performed in mice
showing that M8/9 and M5 IgGs were cleared much faster
compared to complex glycosylated IgGs and thatM8/9 glycans
were in vivo converted to M6.(8) It was concluded that these
faster cleared N-glycans bound to N-glycan specific receptors
and were subsequently removed via endocytosis.(11–13)
Correspondingly, the mannose specific receptor was thought
to bind terminal mannose residues resulting in fast clearance
of high mannose structures.(14–18) In contrast to the immuno-
assay and studies with enriched IgG fractions the results obtain-
ed with LC-MS methods from the human case studies point in
the same direction. However, the published studies have some
drawbacks such as the small number of subjects which does not
allow statistically significant conclusions or the serum sample
volumes do prevent the use of the study setup N-glycan PK
profiling as an accompanying analysis to preclinical studies.
The sample volumes during clinical studies could be sufficient
to generate also data on N-glycoforms, but clinical studies are
performed late from a development perspective and an adjust-
ment of the mAb N-glycosylation based on the findings from
the N-glycan PK profiling is hardly possible at this development
stage. Therefore, it would be advantageous if the influence of
N-glycans could be studied earlier, e.g., already during the
preclinical phase or even in exploratory preclinical studies to
be able to adjust critical quality attributes, for example by glyco-
engineering. The prerequisites for this approach are that the
observed effects during preclinical studies like the increased
clearance of high mannose glycans must be representative for
the results obtained in clinical studies Furthermore, serum sam-
ple consumption must be minimal and the sensitivity of the LC-
MS methods must be increased drastically as serum volume is
more limited in animal studies compared to human studies.
Finally, the throughput of the methods must be increased to
analyze a statistically powerful number of animals. In this study
an analytical approach circumventing the mentioned limita-
tions is presented. The method comprises a high-throughput
sample preparation procedure encompassing affinity purifica-
tion using immobilized antigen and glycan processing. The
work-flow was completely based on 96-well plate format.
Analysis of 2-AA labeled N-glycans was performed with a high-
ly sensitive nanoLCMS using reversed phase chromatography
which was previously shown to be robust and sensitive.(19)
Quantification by MS was achieved using a stable heavy iso-
tope 2-AA label that contains six 13C atoms.(20) The use of this
internal standard compensated for variations in the sample
preparation and resulted in a higher precision of the
nanoLCMS analysis. Together with the small scale sample
preparation N-glycan PK data were obtained from 50 μl serum
samples from an IgG1 s.c. PK study performed in rabbits.
MATERIALS AND METHODS
Materials
2-Aminobenzoic acid, ethanolamine, formic acid, picoline bo-
rane, DMSO, 13C aminobenzoic acid were from Sigma
(Munich, Germany). PNGaseF was from Roche (Penzberg,
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Germany). Acetic acid, acetonitrile and hydrochloric acid
were from Merck (Darmstadt, Germany). NHS activated se-
pharose, Sephadex® G-10 96-well plates and 96-well deep
well plates were from GE Healthcare (Munich, Germany).
Antigen was from Peprotech (Hamburg, Germany).
Phosphate buffered saline was from Gibco/Life technologies
(Darmstadt, Germany).
Multicreen THSHV filter plates were fromMilipore. IdeS
protease was Genovis (Lund, Sweden). 96-well plates were
from Nunc/Thermo Scientific (Munich, Germany).
AcroPrep™AdvanceOmega™ 10K 96-well filter plates were
from Pall (Dreieich, Germany). Preclinical rabbit serum sam-
ples were obtained from clinical bioanalytics at Sandoz.
Methods
Preclinical Rabbit Study
The preclinical study was performed in New Zealand White
(NZW) rabbits. Following single subcutaneous administration
of 10 mg kg−1 b.w. of an IgG1 biopharmaceutical (mAb1)
blood samples were drawn from the vena cephalica or saphena
magna over 29 days including one pre-dose blood sample.
Detailed sampling is listed in Table I. Samples were stored
at −70°C and were thawed at romm temperature immediate-
ly before analysis. Concentration of mAb1 in preclinical se-
rum samples was determined using a sandwich ELISA. Free
mAb1 was quantitatively analyzed using immobilized antigen
and a horse radish peroxidase conjugated probe specifically
binding mAb1 for detection. From remaining serum with one
freeze thaw cycle 2×50 μl aliquots were used for glycan PK
profiling. The first aliquot was analyzed and the second ali-
quot served as back-up aliquot and was stored at −70°C.
Preparation of 13C 2-AA Labeled Glycan Standard
N-glycans of desalted mAb were released, labeled with [13C]
2-AA which contains 6 13C atoms and purified as described
earlier.(19) Purified 13C 2-AA labeled N-glycans (25 pmol/μl)
were aliquoted and stored at −20°C until use.
Preparation of 96-Well Plate Affinity Columns with Immobilized
Antigen
Antigen was dissolved in H2O (1 mg/mL), reconstituted for 2 h
at room temperature and further. diluted (0.5 mg/ml) with
H2O, aliquoted and stored at −20°C until use. Prior to immo-
bilization antigen solutionwas prepared by diluting reconstituted
antigen with PBS to a final concentration of 0.05 mg/ml. The
membranes of a 96 well filter plate were wetted with 1 mMHCl
(100 μL) before addition of 200 μL NHS activated sepharose-
isopropanol slurry per well. Isopropanol was removed by centri-
fugation (100 g) and the columns were washed with 1 mMHCl
(150 μL) for four times. Antigen solution (100 μL) was centri-
fuged (50 g) into the prepared columns and coupling reaction
was allowed to take place for 2 h at ambient temperature.
Affinity columns were washed by centrifugation (50 g) and re-
maining NHS groups were inactivated using ethanolamine buff-
er (150 μL). Finally microplate columns were equilibrated by
centrifugation (50 g) with PBS.
Affinity Purif ication of an IgG1 Biopharmaceutical and Glycan
Processing
Serum samples (50 μL) were diluted with PBS (50 μl) and
applied to the affinity purification column by centrifugation
(50 g). Antigen bound mAb1 was washed several times with
PBS to remove serum and unspecific bound proteins. IdeS
protease solution was centrifuged (50 g) into the columns to
release the glycosylated Fc part of the mAb. Reaction was
performed at 37°C for 30 min. Released Fc parts were eluted
with PBS (2×150 μl) by centrifugation (100 g). Flow through
was collected in new microplates. PNGaseF and 13C-2-AA
labeled N-glycan standards were added. This mixture was
incubated for 17 h at 37°C to release mAb1 N-glycans. N-
glycans were purified by ultrafiltration using 96-well plates
with 10K cut-off membranes. N-glycans (released N-glycans
and 13C 2-AA glycan standard) were dried by vacuum
centrifugation.
Dried N-glycans were dissolved in H2O (10 μL) and
12C 2-
AA labeling solution (15 μL; 100 mg/mL picoline borane,
50 mg/mL 2-AA in a 7:3 mixture of DMSO and acetic acid)
was added to label releasedmAb1 sample N-glycans. Labeling
was performed at 37°C for 17 h.
Excess label was removed by gelfiltration using custom
made 96-well Sephadex G-10 plates. Columns were equili-
brated with 4×200 μL H2O by centrifugation (100 g).
Labeled samples were filled up to 100 μL with H2O and
applied to the gel filtration columns. 2-AA and 13C 2-AA
labeled N-glycans were eluted with 150 μl H2O. Purified gly-
cans were brought to dryness by vacuum centrifugation and
were redissolved in 20 μL H2O for nanoLC-MS analysis.
Table I Sampling Schedule of the Preclinical Study of an IgG1. At Each Sampling Time Point ~500 μl of Serum Were Drawn
Day 1 1 1 2 2 3 3 4 5 8 15 22 29
Hours [post-dose] 0 (pre-dose) 2 8 24 40 48 60 72 96 168 336 504 672
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nanoLCMS of Labeled N-glycans
NanoLCMSwas performed as described earlier.(21) The light to
heavy ratio (L/H) of the co-ionizing 2-AA N-glycans and the
6Da heavier 13C 2-AAN-glycan standard was determined from
the intensities of the monoisotopic peaks. The L/H was deter-
mined for each mAb1 N-glycan and its corresponding standard.
By plotting the L/H ratio over sampling time points the glycan
PK profile was obtained for the individual N-glycans. After nor-
malization to the maximal L/H ratio the glycan PK profiles can
be compared to the normalized ELISA profile. PK parameters
(AUC, t1/2, etc.) were determined and statistical analysis of the
data was performed using Graphpad Prism V6.04.
RESULTS
Preclinical Study and ELISA
The preclinical study was performed in New Zealand White
Rabbits. 15 animals were included in this study. A single sub-
cutaneous dose of an IgG1 biopharmaceutical (mAb1) with
10 mg per kg body weight was administered. Serum samples
were taken at 12 sampling time points after administration
(Table I). Concentration of mAb1 was determined by ELIS
A. (Fig. 1). Remaining serum samples (50 μl) were used for N-
glycan PK profiling.
N-glycan PK Profiling Method Development
and Qualification
To be able to analyze the different N-glycans of mAb1 from
serum samples the antibody had to be affinity purified and
therefore a workflow had been developed which is described
briefly in the following: Affinity columns consisting of NHS
sepharose were prepared in 96 well filter plates. Then 5 μg
mAb1 antigen per well were immobilized by covalent binding
to the NHS groups. Remaining free NHS groups were
deactivated with ethanolamine buffer and equilibrated with
PBS. Recovery of mAb1 from rabbit serum is schematically
shown in Fig. 2. Preclinical serum samples were applied to the
affinity columns. The samples were centrifuged through the
column and the resin was washed several times with PBS to
remove unspecific bound serum proteins. To obtain pure gly-
can samples the glycan containing Fc part of the immobilized
antibody was subsequently specifically released using IdeS en-
zyme. The eluted antibody fragments were deglycosylatied by
use of PNGaseF. Together with PNGaseF a stable heavy iso-
tope standard, 13C 2-AA labeled N-glycans obtained from
mAb1 was added to the samples. Released sample N-glycans
were then labeled with 2-AA and excess label was subsequently
removed by gelfiltration. Labeled N-glycans were analyzed by
nanoLC-MS and the ratio of the peak areas of light sample
glycan and its corresponding heavy isotope standard were de-
termined. This light to heavy ratio (L/H) was determined for
each N-glycan for each sampling time point and animal. By
plotting the average L/H ratio from all 15 animals against time
individual PK profiles for eachN-glycan were obtained. Glycan
maps were calculated for each sampling time point based on
the known L/H ratios and the relative distribution of the heavy
isotope standard glycans which was determined in a separate
nanoLCMS run. To qualify the method for its intended pur-
pose several criteria were determined. The qualification of the
nanoLCMS method was described previously (21). With the
determined maximal antigen binding capacity of 5 μg in the
96-well plates at theoretical ULOQ of 15 μg mAb1 or
250 μg/ml using 50 μl serum could be calculated. Next
LOD, LLOQ and linearity were determined for each N-
glycan in dilution series of mAb1 in neat serum (Table S1).
The LLOQ (10 μg/ml) was approximately three times higher
than the LOD (3 μg/ml). Linearity was determined for each N-
glycan individually with maximal concentrations between 100
and 200 μg/ml (Table S1). Linearity (R2>0.98) plots are
depicted in supplementary Figure S1. Robustness of the meth-
od was assessed by comparing the results of two operators
(Figure S2). Matrix interference was excluded by analyzing
mAb1 N-glycans after spiking into and purification from differ-
ent animal (rabbit, monkey) and human sera. Accuracy was
determined by comparing results of the glycan maps of mAb1
after affinity purification to the one obtained directly from the
drug product (Figure S3). In order to test the method for the
detection of changes of single N-glycans a proof of concept
study was performed by spiking mixtures of mAb1 with increas-
ing portions of degalactosylated mAb1 into rabbit serum and
using the developed method to detect the differences (Table S2
and Figure S4). The first experiment contained exclusively un-
treated mAb1 and served as control experiment. Experiment 1
had therefore constant galactosylation of 18%. In the second
experiment increasing portions of degalactosylated mAb1 were
Fig. 1 ELISA results with range from 15 rabbits that were included in the
preclinical study of an IgG1 biopharmaceutical.
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mixed with untreated mAb1 starting from 0 to 100%
degalactosylated mAb1. Small levels of terminal galactosylation
were detected in the sample containing 100% degalatosylated
mAb1 indicating incomplete degalactosylation. The third
Fig. 2 Glycan PK profiling work-flow. 1. Serum samples are applied to 96-well based affinity purification columns with immobilized antigen (light green). 2. The
column is extensively washed. 3. The N-glycan containing Fc part is released by centrifugation of IdeS enzyme into the column and incubation at 37°C for 30min.
Fab and unspecific bound proteins remain on the column. 4. PNGaseF and heavy isotope standard (13C 2-AA N-glycans) are added to the Fc part. Incubation for
17 h at 37°C. 5. Released sample N-glycans and heavy isotope standard are purified from proteins by ultrafiltration. 6. 2-AA labeling of sample glycans and
subsequent gelfiltration to remove excess label. 7. NanoLC-MS analysis.
Fig. 3 Average glycan map
obtained from 10; 50 and
100 μg/ml quality check samples
shows the relative N-glycan
composition. Error bars show the
standard error.
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dilution series reflected decreasing galactosylation from 18% to
approximately 15% which corresponds a relative decrease
by 15%. Considering an incomplete degalactosylation as
seen for experiment 2 this result demonstrated that a
relative decrease of 15% terminal galactosylation can
be detected. In experiment 4 where a decrease of 5%
galactosylation was prepared no significant decrease
compared to the control was observed. Thus the de-
crease of individual N-glycans should be at least 10–15%
(relative to initial portion) in order to be detected with the
developed approach. The linear range between 10 and
100 μg/ml when using 50 μl of serum samples was sufficient
to analyze the rabbit study.
mAb1 N-glycosylation and Qualification of the Study
To control the affinity purification quality check samples
were prepared by spiking known amounts of mAb1 into
NZW rabbit serum. The quality check samples covered
the concentration range of the study which was previ-
ously determined by ELISA. Figure 3 shows the mean
glycan maps of the 10, 50 and 100 μg/ml mAb1 quality
check samples. With the developed enzymatic elution of
the glycosylated antibody fragments very high selectivity
and purity was achieved. No interfering N-glycans of
mAb1 were co-purified with the exception of two minor
abundant bisecting variants that were excluded from
analysis. No additional serum related N-glycans were
detected. Sensitivity was sufficient to analyze all N-
glycans with a percentage of at least 0.1% at a concen-
tration of 10 μg/ml. The N-glycans were mainly complex
biantennary with core fucose. The most abundant N-glycan
was G0F (65%) with terminal N-acetylglucosamine resi-
dues followed by G1F (16%) with one additional termi-
nal galactose. High mannose glycan M5 (9.5%) was the
third most abundant N-glycan. All other N-glycans had
a portion of less than 3%. mAb1 contained no N-
glycans with terminal sialic acids. Glycan structures are
shown in Fig. 4.
Glycan PK Profiles of mAb1
The determined glycan L/H ratios were plotted against the
sampling time to obtain individual PK profiles for each N-
glycan. Mean L/H ratios for each N-glycan were normalized
to the maximum of each N-glycan L/H curve to obtain a
relative concentration (Fig. 5). ELISA data were normalized
in the same way. The PK profile of the most abundant com-
plex type G0F was very similar to the ELISA profile (Fig. 5a).
The maximum concentration (tmax) was reached after 72 h
with congruency of the ELISA and the L/H glycan graph.
Elimination occured at identical rates and the PK profiles
were regarded as comparable. This finding was expected as
the ELISA represents the average profile of all mAb1
glycoforms and G0F being the major N-glycan representing
the majority of these glycoforms. The second most abundant
complex type N-glycan G1F that accounted for approximate-
ly 16% of all mAb1 N-glycans also showed a PK profile which
was very similar compared to the ELISA profile (Fig. 5b).
Again tmax was reached at 72 h. Complex type G2F with a
portion of 2% had the best match with the ELISA profile
showing almost perfect congruency (Fig. 5c). The profile of
the M6G0F/M5G1F hybrid type glycan represented two iso-
mers that could not be differentiated with the nanoLC-MS
approach and which had a relative content of only 0.1%.
The profile and tmax were similar to the ELISA profile as well
(Fig. 5d). The low abundance brought the analysis close to the
LLOQwhich resulted in lower precision and higher variation.
The glycan PK profiles ofM3,M3G0F andM3G1F were also
highly similar to the ELISA profile (Fig. 5e, f and g). These
results demonstrated that PK profiles could be obtained for
each N-glycan individually. The complex glycan PK profiles
were highly similar to the ELISA for the most abundant gly-
cans. For N-glycans with a portion smaller than 0.5% the
graphs showed higher variation. Considering all the glycan
Fig. 4 N-glycan structures of mAb1. Blue square stands for N-Acetylglucosamine, green circle for mannose, yellow circle for galactose and red triangle for fucose.
Fig. 5 Comparison of nanoLC-MS based glycan PK data (blue) and ELISA
data (red) for G0F (a), G1F (b), G2F (c), M5G1F/M6G0F (d), M3 (e), M3G1F
(f), M3G0F (g). Concentration is relative to the maximum of each curve to
enable comparison. Mean profiles from 15 animals are shown.
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forms analyzed, only the high mannose type N-glycans M5
and M6 with 9.5 and 2% relative abundance respectively
showed a clear discrepancy from the ELISA profile (Fig. 6)
The maximum concentration of M6 was reached after 24 h
followed by either a conversion to M5 or an increased elimi-
nation rate that led to a faster clearance to a level below the
LLOD or a complete removal from circulation at the 168 h
time point. The high mannose glycan M5 profile also differed
from the overall mAb ELISA PK profile (Fig. 6b). The tmax
was reached 24 h earlier already after 48 h and these mole-
cules were cleared faster between 48 and 168 h. PK profiles
for G0 could not be obtained due to co-elution of a contam-
inant with the same m/z value. The tmax values are listed in
Table II.
Relative Decrease of M5 and M6
As shown above highmannose glycan PKprofiles differed from
the ELISA profile of mAb1 which represented the average
concentration of all protein variants. These findings are
reflected in the glycanmaps calculated for sampling time points
between 8 and 336 h (Fig. 7a).. At 2, 504 and 672 h the mAb1
serum concentration was below the LLOQ of 10 μg/ml. The
glycan map of the QC samples as shown in Fig. 3 is depicted as
well. Changes in the glycan composition of mAb 1 during cir-
culation through selective clearance or conversion would result
in a decrease or increase in the glycan map. Mean percentages
of the most abundant N-glycans G0F and G1F stayed constant
indicating no change over time which confirmed the previously
made observations based on the glycan PK profiles (Fig. 7a).
The glycan maps illustrate that the contribution of all N-
glycans was constant except for the high mannose glycans M5
and M6 portions which decreased over time. The increase of
G2F at 336 h was due to a single outlier in one animal. M6 was
removed from circulation completely or below the LLOQ
within 168 h whereas the M5 portion decreased after a small
initial increase from the initial percentage of 9% to approxi-
mately 4% after 336 h. The value of M5 increase corresponds
to the M6 decrease within the same time frame. Dot plots
showing the percentages of M5 and M6 (Fig. 7c and d) for
the individual rabbits demonstrate that the trending was ob-
served in all animals and not due to single outliers. G1F was
plotted as a constant reference (Fig. 7b).
The relative quantification of individual N-glycans and
thereof obtained glycan PK profiles allow the determination
of several pharmacokinetic parameters like tmax, t1/2 and the
AUC from the mean PK profiles of all 15 animals (Table II).
Values for the two M5G1F/M6G0F isomers were not deter-
mined because of the low abundance (~0.1%). The tmax, t1/2
and AUC of the ELISA representing the average glycosylated
molecule are depicted too serving as a reference. The tmax of
the ELISA (72 h) is identical with the two most abundant
glycans G0F andG1F. Elimination half-lifes are similar as well
demonstrating the accuracy and precision of the glycan PK
approach. M6 has the lowest tmax with 24 h followed by M5
and G2F (48 h). M6 and M5 had the lowest elimination half-
Fig. 6 Comparison of high mannose glycan M6 (a) and M5 (b) PK profiles obtained by nanoLC-MS (diamond) and ELISA (squares) profiles.
Table II Pharmacokinetic Parameters of Individual N-glycans Obtained from PK Profiles. The Time Until the Maximal Concentration (tmax), the Elimination
Half-life (t1/2) and the Area Under the Curve (AUC) Were Determined for Each N-glycan and the ELISA from the Average of All 15 Animals. Relative AUCs of Each
N-glycan Were Tested for Significantly Difference to the ELISA AUC with Unpaired t-tests
M6 M5 M3 G2F G1F M3G1F M3G0F G0F ELISA
tmax [h] 24 48 72 48 72 96 72 72 72
t1/2 [d] 0.7 12.6 13.0 14.5 13.9 13.3 13.3 13.8 14.8
Relative AUC [0-672] 44 214 231 258 257 231 233 256 270
Significant different to ELISA (p<0.05) Yes p<0.0001 Yes p=0.0175 No No No No No No ND
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life and the AUC. The differences reflect the observed de-
crease seen in the glycan maps. M6 is rapidly removed where-
as M5 is removed at a slower rate. Relative AUCs of the
individual N-glycans were tested with unpaired t-test for sig-
nificance of differences (p<0.05) compared to the ELISA. M5
(p=0.0175) and M6 (p<0.0001) were statistically significant
different to the ELISA (Table II and Figure S5).
DISCUSSION
An innovative approach for the investigation of individual N-
glycan pharmacokinetics was utilized to analyze a preclinical
rabbit study of an IgG1 biopharmaceutical. Using 96 well
plates based high throughput affinity purification with the
immobilized antigen and a stable heavy isotope standard
nanoLC-MS quantification glycan it was possible to obtain
PK data from only 50 μl serum samples for mAb concentra-
tions between 10 and 90 μg/ml. A rabbit study including 15
animals was successfully analyzed and demonstrated the fea-
sibility of the developed approach as an accompanying meth-
od in preclinical development. PK profiles for individual N-
glycans were obtained which was so far not described in liter-
ature. These glycan PK profiles were compared to ELISA
data demonstrating that high mannose glycans M5 and M6
had a statistically different PK profile. Glycan maps showed
Fig. 7 Glycan Maps of mAb1 for each time point. (a) Mean percentage and standard error of recovered mAb1 N-glycans after single subcutaneous admin-
istration in rabbits. The glycanmap of the spiked QC samples is shown as reference. Dot plots showing the glycan percentages of individual rabbits for G1F (b), M5
(c) and M6 (d).
Table III Portions of Glycoforms Containing M5. Theoretical Values Were Calculated Based on the Assumption of Random Pairing. Observed Values Were
Obtained from MS Analysis of intact mAb1
M5:M5 M5:G1F M5:M3G1F M5:G0F M5:M3G0F G0F:G0F
Calculated relative 0.62% 1.12% 0.11% 5.29% 0.18% 45.43%
Calculated relative to the most abundant G0F:G0F 1.36% 2.46% 0.24% 11.64% 0.40% 100%
Observed relative to the most abundant G0F:G0F 5.13% ND ND 12.73% ND 100%
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that M6 was either removed below the LLOQ or was
completely removed during the first 48 h and M5 levels de-
creased from 9.5% to approximately 4%. These differences of
M5 andM6 decrease were reflected in the elimination half-life
and tmax. The elimination half-life of M6 is only 0.7 days in-
dicating a fast mechanism of removal. M5 has a longer elim-
ination half-life yet still shorter than half-life of all other N-
glycans indicating a different second mechanism of removal
from the circulation. High mannose species M6-M9 are most
likely converted by glycosidases in circulation to the smaller
high mannose glycans M5 in humans (6,9). In mice a similar
observation was made as high mannose species M7-M9 were
converted to M6 (8). In the present study an initial increase of
M5 and decrease of M6 was observed indicating a fast in vivo
conversion fromM6 toM5. However, these conversionmech-
anisms are not applicable for theM5 glycoform because of the
enzyme specificity. Removal of mannose residues from M6-
M9 requires cleavage of α 1,2 glycosidic bonds whereas M5
terminal mannose residues are connected via α 1,3 and α 1,6
glycosidic bonds. This is in agreement with the observation of
constantM3; M4 glycans were not detected in the IgG used in
the present study. The fast decrease in M5 can be explained
by a secondmechanism.M5 and in conclusionM5 containing
glycoforms are probably removed by a specific clearance
mechanism from circulation involving the mannose receptor
which binds amongst others specifically to mannose contain-
ing glycoproteins and removes them from circulation with
similar functions in humans and rabbits that were described
previously (11,12,14,16,17,22). The incomplete removal of
M5 from circulation observed in this study can be explained
by the structural conformation of the Fc part. Several investi-
gations showed that IgGs exhibiting N-glycans with terminal
galactosylation on both heavy chains change the conformation
of the Fc part to a horseshoe conformation which makes the
N-glycans accessible for receptors (23). The mannose receptor
is then able to bind M5 and remove the IgG molecules from
circulation. It was shown that the assembly of the glycosylated
heavy chains during protein biosynthesis in the ER is not
random (24). For an IgG2 biopharmaceutical it was demon-
strated that the glycoformM5:M5 is favored (7). For mAb1 in
the present study a similar observation was made (Table III).
Assuming random pairing all theoretical glycoforms percent-
ages can be calculated which is shown in Table III for most
abundant M5 containing glycoforms. MS data from intact
mAb1 showed that the M5:M5 glycoform content was four
times higher than the theoretical value assuming random
heavy chain assembly. Thus M5:M5 was strongly favored
during protein biosynthesis. The mAb1 Fc part with this
glycoform combination may exhibit a horseshoe conforma-
tion which in turn results in an increased clearance from cir-
culation by binding to the Mannose receptor. The remaining
4%M5 observed in the preclinical study were probably mAb1
molecules containing M5 in combination with G0F and other
glycoforms that are small enough for a closed Fc conforma-
tion. Other glycoforms with an open Fc part could be
M5:G1F or M5:G2F. However analysis of these glycoforms
was not possible for mAb1 because of the major glycoforms
overlaying the M5:G1F and M5:G2F glycoforms in the intact
mass spectrum. Overall, the study results are similar to data
from human case studies (6,7), which demonstrates the value
of glycan PK profiling with preclinical samples. However, the
observed disappearance of M6 appears to be contradictory to
literature. It was reported that after an initial decrease of M6
by about 50% the levels remain fairly constant over time (6,9).
It could be speculated that in the present case M6 disappears
due to a different M6 removal or conversion mechanism in
rabbits.
In summary, an innovative approach for glycan PKprofiling
of N-glycans was developed. Due to its high sensitivity samples
from preclinical studies with low available sample volumes
could be analyzed. The miniaturized work-flow in 96-well
plates allows the preparation of many samples in parallel. The
preclinical study results confirm previous findings from individ-
ual human case studies and therefore are representative for
clinical studies. Thus the effect of N-glycosylation can be pre-
dicted by preclinical studies and detected earlier in biopharma-
ceutical development which allows optimizing N-glycosylation
via glyco-engineering before entering clinical phases.
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